{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:29:54Z","timestamp":1792794594648,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100003358","name":"Gedeon Richter","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003358","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00198-025-07711-x","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T15:25:56Z","timestamp":1760455556000},"page":"2497-2507","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A randomised Phase 3 study comparing the efficacy and safety of proposed denosumab biosimilar RGB-14-P and reference denosumab in women with postmenopausal osteoporosis"],"prefix":"10.1007","volume":"36","author":[{"given":"Lothar","family":"Seefried","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9nes","family":"P\u00e1ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ombretta","family":"Viapiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"Supronik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodina Nestorova","family":"Licheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Kiefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Jeszen\u0151i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00e1roly","family":"Horv\u00e1t-Karajz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enik\u0151","family":"J\u00f3kai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"Tak\u00e1cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"7711_CR1","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/s0140-6736(18)32112-3","volume":"393","author":"JE Compston","year":"2019","unstructured":"Compston JE, McClung MR, Leslie WD (2019) Osteoporosis. Lancet 393:364\u2013376. https:\/\/doi.org\/10.1016\/s0140-6736(18)32112-3","journal-title":"Lancet"},{"key":"7711_CR2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12325-021-01936-y","volume":"39","author":"DL Kendler","year":"2022","unstructured":"Kendler DL, Cosman F, Stad RK, Ferrari S (2022) Denosumab in the treatment of osteoporosis: 10 years later: a narrative review. Adv Ther 39:58\u201374. https:\/\/doi.org\/10.1007\/s12325-021-01936-y","journal-title":"Adv Ther"},{"key":"7711_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115493","volume":"139","author":"MJ Rogers","year":"2020","unstructured":"Rogers MJ, Monkkonen J, Munoz MA (2020) Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton. Bone 139:115493. https:\/\/doi.org\/10.1016\/j.bone.2020.115493","journal-title":"Bone"},{"key":"7711_CR4","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.4065\/83.9.1032","volume":"83","author":"MT Drake","year":"2008","unstructured":"Drake MT, Clarke BL, Khosla S (2008) Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83:1032\u20131045. https:\/\/doi.org\/10.4065\/83.9.1032","journal-title":"Mayo Clin Proc"},{"key":"7711_CR5","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1111\/ijcp.12022","volume":"66","author":"DA Hanley","year":"2012","unstructured":"Hanley DA, Adachi JD, Bell A, Brown V (2012) Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract 66:1139\u20131146. https:\/\/doi.org\/10.1111\/ijcp.12022","journal-title":"Int J Clin Pract"},{"key":"7711_CR6","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765. https:\/\/doi.org\/10.1056\/NEJMoa0809493","journal-title":"N Engl J Med"},{"key":"7711_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1359\/jbmr.0809010","volume":"24","author":"JP Brown","year":"2009","unstructured":"Brown JP, Prince RL, Deal C et al (2009) Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 24:153\u2013161. https:\/\/doi.org\/10.1359\/jbmr.0809010","journal-title":"J Bone Miner Res"},{"key":"7711_CR8","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1093\/jbmr\/zjae079","volume":"39","author":"JR Curtis","year":"2024","unstructured":"Curtis JR, Arora T, Liu Y et al (2024) Comparative effectiveness of denosumab vs alendronate among postmenopausal women with osteoporosis. J Bone Miner Res 39:826\u2013834. https:\/\/doi.org\/10.1093\/jbmr\/zjae079","journal-title":"J Bone Miner Res"},{"key":"7711_CR9","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJMoa0809003","volume":"361","author":"MR Smith","year":"2009","unstructured":"Smith MR, Egerdie B, Hernandez Toriz N et al (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361:745\u2013755. https:\/\/doi.org\/10.1056\/NEJMoa0809003","journal-title":"N Engl J Med"},{"key":"7711_CR10","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1210\/jc.2012-1569","volume":"97","author":"E Orwoll","year":"2012","unstructured":"Orwoll E, Teglbjaerg CS, Langdahl BL et al (2012) A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab 97:3161\u20133169. https:\/\/doi.org\/10.1210\/jc.2012-1569","journal-title":"J Clin Endocrinol Metab"},{"key":"7711_CR11","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S2213-8587(18)30075-5","volume":"6","author":"KG Saag","year":"2018","unstructured":"Saag KG, Wagman RB, Geusens P et al (2018) Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol 6:445\u2013454. https:\/\/doi.org\/10.1016\/S2213-8587(18)30075-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"7711_CR12","unstructured":"(2024) Denosumab (Prolia) [Prescribing information]. Amgen Manufacturing Limited, Thousand Oaks, California. https:\/\/www.pi.amgen.com\/-\/media\/Project\/Amgen\/Repository\/pi-amgen-com\/Prolia\/prolia_pi.pdf. Acessed Oct 2025"},{"key":"7711_CR13","unstructured":"(2025) Denosumab (Prolia) [Summary of product characteristics]. Amgen Europe B.V. 2025, Breda, The Netherlands. https:\/\/www.medicines.org.uk\/emc\/product\/568\/smpc. Accessed Oct 2025"},{"key":"7711_CR14","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5:513\u2013523. https:\/\/doi.org\/10.1016\/S2213-8587(17)30138-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"7711_CR15","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1210\/jc.2018-02236","volume":"104","author":"H Lyu","year":"2019","unstructured":"Lyu H, Jundi B, Xu C et al (2019) Comparison of denosumab and bisphosphonates in patients with osteoporosis: a meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 104:1753\u20131765. https:\/\/doi.org\/10.1210\/jc.2018-02236","journal-title":"J Clin Endocrinol Metab"},{"key":"7711_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-024-01447-7","volume":"19","author":"M Li","year":"2024","unstructured":"Li M, Ge Z, Zhang B et al (2024) Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials. Arch Osteoporos 19:89. https:\/\/doi.org\/10.1007\/s11657-024-01447-7","journal-title":"Arch Osteoporos"},{"key":"7711_CR17","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1002\/jbmr.81","volume":"25","author":"E Seeman","year":"2010","unstructured":"Seeman E, Delmas PD, Hanley DA et al (2010) Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res 25:1886\u20131894. https:\/\/doi.org\/10.1002\/jbmr.81","journal-title":"J Bone Miner Res"},{"key":"7711_CR18","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00198-019-05233-x","volume":"31","author":"PD Miller","year":"2020","unstructured":"Miller PD, Pannacciulli N, Malouf-Sierra J et al (2020) Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates. Osteoporos Int 31:181\u2013191. https:\/\/doi.org\/10.1007\/s00198-019-05233-x","journal-title":"Osteoporos Int"},{"key":"7711_CR19","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/jbmr.3427","volume":"33","author":"F Cosman","year":"2018","unstructured":"Cosman F, Crittenden DB, Ferrari S et al (2018) FRAME study: the foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab. J Bone Miner Res 33:1219\u20131226. https:\/\/doi.org\/10.1002\/jbmr.3427","journal-title":"J Bone Miner Res"},{"key":"7711_CR20","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","volume":"386","author":"BZ Leder","year":"2015","unstructured":"Leder BZ, Tsai JN, Uihlein AV et al (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 386:1147\u20131155. https:\/\/doi.org\/10.1016\/S0140-6736(15)61120-5","journal-title":"Lancet"},{"key":"7711_CR21","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2023.5429","volume":"5","author":"K Feng","year":"2024","unstructured":"Feng K, Russo M, Maini L, Kesselheim AS, Rome BN (2024) Patient out-of-pocket costs for biologic drugs after biosimilar competition. JAMA Health Forum 5:e235429. https:\/\/doi.org\/10.1001\/jamahealthforum.2023.5429","journal-title":"JAMA Health Forum"},{"key":"7711_CR22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40273-020-00965-9","volume":"39","author":"N Li","year":"2021","unstructured":"Li N, Cornelissen D, Silverman S et al (2021) An updated systematic review of cost-effectiveness analyses of drugs for osteoporosis. Pharmacoeconomics 39:181\u2013209. https:\/\/doi.org\/10.1007\/s40273-020-00965-9","journal-title":"Pharmacoeconomics"},{"key":"7711_CR23","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s40259-025-00738-w","volume":"39","author":"AS Garai","year":"2025","unstructured":"Garai AS, Huse D, Fizil A et al (2025) Comprehensive physico-chemical and functional similarity assessment study of RGB-14-P and RGB-14-X drug products as proposed biosimilars to denosumab reference products. BioDrugs 39:697\u2013724. https:\/\/doi.org\/10.1007\/s40259-025-00738-w","journal-title":"BioDrugs"},{"key":"7711_CR24","unstructured":"ClinicalTrials.gov (2024) Comparative efficacy and safety study of RGB-14-P and prolia\u00ae in women with postmenopausal osteoporosis: NCT05087030.  https:\/\/clinicaltrials.gov\/study\/NCT05087030.  Accessed 25 Mar 2025"},{"issue":"Suppl 3","key":"7711_CR25","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1007\/s00198-002-1348-1","volume":"14","author":"HK Genant","year":"2003","unstructured":"Genant HK, Jergas M (2003) Assessment of prevalent and incident vertebral fractures in osteoporosis research. Osteoporos Int 14(Suppl 3):S43\u201355. https:\/\/doi.org\/10.1007\/s00198-002-1348-1","journal-title":"Osteoporos Int"},{"key":"7711_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2025.113878","volume":"541","author":"T Pap","year":"2025","unstructured":"Pap T, Kir\u00e1ly N, Fekete A, T\u00f3th JP, K\u00f3nya A (2025) Target tolerance improvement of the immunogenicity assay developed for analysing samples from clinical trials of RGB-14, a proposed biosimilar to Prolia\/Xgeva. J Immunol Methods 541:113878. https:\/\/doi.org\/10.1016\/j.jim.2025.113878","journal-title":"J Immunol Methods"},{"key":"7711_CR27","unstructured":"Services USDoHaH, Administration FaD (2016) Clinical pharmacology data to support a demonstration of biosimilarity to a reference product. https:\/\/www.fda.gov\/media\/70958\/download Accessed 31 Jan 2025"},{"key":"7711_CR28","unstructured":"Agency EM (2010) Guideline on the investigation of bioequivalence. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-bioequivalence-rev1_en.pdf Accessed 31 Jan 2025"},{"key":"7711_CR29","doi-asserted-by":"publisher","first-page":"246","DOI":"10.11005\/jbm.2024.31.3.246","volume":"31","author":"J Lee","year":"2024","unstructured":"Lee J, Lee YJ, Ha J (2024) Denosumab in osteoporosis: predicting long-term efficacy beyond 10 years. J Bone Metab 31:246\u2013249. https:\/\/doi.org\/10.11005\/jbm.2024.31.3.246","journal-title":"J Bone Metab"},{"key":"7711_CR30","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s00198-021-06268-9","volume":"33","author":"Y Wan","year":"2022","unstructured":"Wan Y, Zeng F, Tan H et al (2022) Cost-effectiveness analyses of denosumab for osteoporosis: a systematic review. Osteoporos Int 33:979\u20131015. https:\/\/doi.org\/10.1007\/s00198-021-06268-9","journal-title":"Osteoporos Int"},{"key":"7711_CR31","doi-asserted-by":"publisher","first-page":"151939","DOI":"10.1016\/j.semarthrit.2021.11.009","volume":"52","author":"TK Kvien","year":"2022","unstructured":"Kvien TK, Patel K, Strand V (2022) The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems. Semin Arthritis Rheum 52:151939","journal-title":"Semin Arthritis Rheum"},{"key":"7711_CR32","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1002\/jbmr.4705","volume":"37","author":"F Cosman","year":"2022","unstructured":"Cosman F, Huang S, McDermott M, Cummings SR (2022) Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses. J Bone Miner Res 37:2112\u20132120. https:\/\/doi.org\/10.1002\/jbmr.4705","journal-title":"J Bone Miner Res"},{"key":"7711_CR33","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1210\/jc.2016-3170","volume":"102","author":"O Lamy","year":"2017","unstructured":"Lamy O, Gonzalez-Rodriguez E, Stoll D, Hans D, Aubry-Rozier B (2017) Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report. J Clin Endocrinol Metab 102:354\u2013358. https:\/\/doi.org\/10.1210\/jc.2016-3170","journal-title":"J Clin Endocrinol Metab"},{"key":"7711_CR34","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1093\/ejendo\/lvaf013","volume":"192","author":"KH Lu","year":"2025","unstructured":"Lu KH, Wang SI, Yang SF (2025) Denosumab withdrawal increases vertebral fracture and mortality risk compared with zoledronate. Eur J Endocrinol 192:180\u2013190. https:\/\/doi.org\/10.1093\/ejendo\/lvaf013","journal-title":"Eur J Endocrinol"},{"key":"7711_CR35","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3803\/EnM.2021.1369","volume":"37","author":"WL Tay","year":"2022","unstructured":"Tay WL, Tay D (2022) Discontinuing denosumab: can it be done safely? A review of the literature. Endocrinol Metab (Seoul) 37:183\u2013194. https:\/\/doi.org\/10.3803\/EnM.2021.1369","journal-title":"Endocrinol Metab (Seoul)"},{"key":"7711_CR36","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/jbmr.3194","volume":"33","author":"DM Black","year":"2018","unstructured":"Black DM, Cauley JA, Wagman R et al (2018) The ability of a single BMD and fracture history assessment to predict fracture over 25 years in postmenopausal women: the study of osteoporotic fractures. J Bone Miner Res 33:389\u2013395. https:\/\/doi.org\/10.1002\/jbmr.3194","journal-title":"J Bone Miner Res"},{"key":"7711_CR37","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1136\/bmj.312.7041.1254","volume":"312","author":"D Marshall","year":"1996","unstructured":"Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254\u20131259. https:\/\/doi.org\/10.1136\/bmj.312.7041.1254","journal-title":"BMJ"},{"key":"7711_CR38","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1093\/jbmr\/zjae040","volume":"39","author":"M Schini","year":"2024","unstructured":"Schini M, Vilaca T, Vittinghoff E et al (2024) Influence of age on the efficacy of pharmacologic treatments on fracture risk reduction and increases in BMD: RCT results from the FNIH-ASBMR-SABRE project. J Bone Miner Res 39:544\u2013550. https:\/\/doi.org\/10.1093\/jbmr\/zjae040","journal-title":"J Bone Miner Res"},{"key":"7711_CR39","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S2213-8587(20)30159-5","volume":"8","author":"DM Black","year":"2020","unstructured":"Black DM, Bauer DC, Vittinghoff E et al (2020) Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials. Lancet Diabetes Endocrinol 8:672\u2013682. https:\/\/doi.org\/10.1016\/S2213-8587(20)30159-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"7711_CR40","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S2213-8587(24)00092-5","volume":"12","author":"DM Black","year":"2024","unstructured":"Black DM, Thompson AR, Eastell R, Bouxsein ML (2024) Bone mineral density as a surrogate endpoint for fracture risk reduction in clinical trials of osteoporosis therapies: an update on SABRE. Lancet Diabetes Endocrinol 12:371\u2013373. https:\/\/doi.org\/10.1016\/S2213-8587(24)00092-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"7711_CR41","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/jbmr.4433","volume":"37","author":"R Eastell","year":"2022","unstructured":"Eastell R, Vittinghoff E, Lui LY et al (2022) Validation of the surrogate threshold effect for change in bone mineral density as a surrogate endpoint for fracture outcomes: the FNIH-ASBMR SABRE project. J Bone Miner Res 37:29\u201335. https:\/\/doi.org\/10.1002\/jbmr.4433","journal-title":"J Bone Miner Res"},{"key":"7711_CR42","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2147\/BTT.S124476","volume":"11","author":"JR Tesser","year":"2017","unstructured":"Tesser JR, Furst DE, Jacobs I (2017) Biosimilars and the extrapolation of indications for inflammatory conditions. Biologics 11:5\u201311. https:\/\/doi.org\/10.2147\/BTT.S124476","journal-title":"Biologics"},{"key":"7711_CR43","unstructured":"(2024) Denosumab (Xgeva) [Prescribing information]. Amgen Inc,\u00a0Thousand Oaks, California.\u00a0www.pi.amgen.com\/-\/media\/Project\/Amgen\/Repository\/pi-amgen-com\/Xgeva\/xgeva_pi.pdf. Accessed Oct 2025"},{"key":"7711_CR44","unstructured":"(2024) Denosumab (Xgeva) [Summary of product characteristics]. Amgen Europe B.V. 2024,\u00a0Breda, The Netherlands.\u00a0www.ema.europa.eu\/en\/documents\/product-information\/xgeva-epar-product-information_en.pdf. Accessed Oct 2025"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07711-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-025-07711-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07711-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T13:31:11Z","timestamp":1764682271000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-025-07711-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["7711"],"URL":"https:\/\/doi.org\/10.1007\/s00198-025-07711-x","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The conduct of this clinical study met all local legal and regulatory requirements and was in accordance with the Declaration of Helsinki. The study protocol was approved by the Institutional Review Board or Independent Ethics Committee for each study site before the start of the study (see\n                      \n                      for details).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"LS, SF\u00a0and IT report receiving consulting and lecture fees from Gedeon Richter; JK, NJ, KH-K\u00a0and EJ are employees at Gedeon Richter; DP, JR, JS, OV\u00a0and RNL have no conflicts of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}